Batoclimab is an investigational drug belonging to the FcRn inhibitor class. This page compares Batoclimab with other FcRn inhibitors such as Efgartigimod (Vyvgart) and Rozanolixizumab (Rystiggo). Key distinctions among these agents often involve their administration routes, dosing frequencies, and approved indications.
Batoclimab Alternatives: How It Compares to Other FcRn Inhibitors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/4 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
Approved comparators include Efgartigimod (Vyvgart) in 2021 and Rozanolixizumab (Rystiggo) in 2023, with pipeline candidates Batoclimab and IMVT-1402 still in Phase 3, potentially 1-2 years behind the most recent approval.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Batoclimab | FcRn inhibitor | — | 340 mg or 680 mg subcutaneously once weekly | Pipeline | Change in MG-ADL score: 5.6points @ Week 12 | — |
| Efgartigimod (Vyvgart) | Neonatal Fc receptor blocker | generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy | 10 mg/kg intravenously or 1,008 mg subcutaneously once weekly for 4 weeks per treatment cycle. Subsequent cycles are administered based on clinical evaluation. | 2021 | MG-ADL responders (≥2-point improvement sustained for ≥4 weeks): 67.7% @ Cycle 1 | $450k |
| Rozanolixizumab (Rystiggo) | Neonatal Fc receptor (FcRn) antagonist | generalized myasthenia gravis | Subcutaneous infusion once weekly for 6 weeks | 2023 | -3.4points @ Day 43 | $437k |
| IMVT-1402 | FcRn inhibitor | — | Subcutaneous | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is MG-ADL change from baseline; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for generalized myasthenia gravis specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Batoclimab vs Efgartigimod (Vyvgart)
No head-to-head Phase-3 trial directly compares Batoclimab with Efgartigimod.
In separate pivotal trials, Batoclimab reported 5.6points Change in MG-ADL score at Week 12 (NCT05403541) versus 67.7% MG-ADL responders (≥2-point improvement sustained for ≥4 weeks) at Cycle 1 for Efgartigimod (NCT03669588).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Batoclimab vs Rozanolixizumab (Rystiggo)
No head-to-head Phase-3 trial directly compares Batoclimab with Rozanolixizumab.
In separate pivotal trials, Batoclimab reported 5.6points Change in MG-ADL score at Week 12 (NCT05403541) versus -3.4points MG-ADL change from baseline at Day 43 for Rozanolixizumab (NCT03971422).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Among investigational therapies, IMVT-1402 from Immunovant Sciences GmbH is currently in active Phase 3 development. This FcRn inhibitor is being evaluated in a lead Phase 3 trial, NCT07039916. Like Batoclimab, IMVT-1402 targets FcRn, representing a similar mechanistic approach.
Choosing between Batoclimab and its alternatives
Batoclimab, an FcRn inhibitor, offers a targeted approach to reducing pathogenic IgG antibodies. While specific efficacy and dosing data for Batoclimab are not detailed here, clinicians may consider its mechanism of action as a basis for selection. The choice of Batoclimab could be influenced by factors such as a potentially distinct safety profile, an administration route that aligns with patient preference, or future data demonstrating specific advantages in efficacy or indication breadth compared to other FcRn inhibitors.
In contrast, other FcRn inhibitors provide established efficacy profiles and dosing regimens. Efgartigimod (Vyvgart) demonstrated a 67.7% MG-ADL responder rate (defined as a ≥2-point improvement sustained for ≥4 weeks) at Cycle 1. It is administered as 10 mg/kg intravenously or 1,008 mg subcutaneously once weekly for 4 weeks per treatment cycle, with subsequent cycles based on clinical evaluation. Rozanolixizumab (Rystiggo) showed a mean MG-ADL change from baseline of -3.4 points at Day 43, with dosing involving subcutaneous infusion once weekly for 6 weeks. Clinicians might prefer these agents when a longer track record, specific efficacy data, or a particular administration route (e.g., intravenous vs. subcutaneous) aligns better with patient needs or existing clinical practice.
This information is not medical advice; clinical decisions should always be made by the prescriber in consultation with the patient.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
batoclimabbatoclimab alternativesalternativescomparisongeneralized myasthenia gravisfcrn-generalized-myasthenia-gravisbatoclimab vs efgartigimodbatoclimab vs rozanolixizumabbatoclimab vs imvt-1402